Вы находитесь на странице: 1из 15

Getting to know

Wyeth Nutrition

Bill Partyka
VP Brand Management
and Innovation
A rich history: launches, innovations
Many landmark achievements, 2011
beginning with the Pfizer launches
creation of the first physiologic 1996
ILLUMA, a super-
premium line
infant formula Launch of AR, an anti-regurgitation
formula, in several countries
Wyeth Pharma dedicates global
1910 resources
First serious scientific effort to create a
physiologic formula. Dr. Gerstenberger begins
quest for a nutritionally complete product
patterned after human milk

2009
GOLD line upgrade

2011
Pfizer Nutrition launched
1997 GOLD brand upgrades in
1933 multiple markets
Introduction of lactose-
1919 SMA Corporation free (LF) formula
becomes worlds
SMA was born; bottles major supplier of
prepared in hospital carotene
kitchen and delivered to
Cleveland physicians

2 September 30th, 2013 Nestl Investor Seminar 2013


Disclaimer
This presentation contains forward looking
statements which reflect Managements current
views and estimates. The forward looking
statements involve certain risks and uncertainties
that could cause actual results to differ materially
from those contained in the forward looking
statements. Potential risks and uncertainties
include such factors as general economic
conditions, foreign exchange fluctuations,
competitive product and pricing pressures and
regulatory developments.

September 30th, 2013 Nestl Investor Seminar 2013


3
A rich history: ownership, acquisitions
2009
1931
Pfizer Inc acquires Wyeth Nutrition
Laboratory Products Company changes renames the business unit Pfizer
name to SMA Corporation Nutrition

1938
American Home Products (now known as
Wyeth) acquires SMA Corporation

2012
Pfizer Nutrition acquired
by Nestl S.A., and is
once again named Wyeth
Nutrition
1943
SMA Corporation becomes main nutritional
division of newly formed Wyeth, Inc

1921
Birth of modern infant formula industry. Telling-Belle Vernon
Company forms the Laboratory Products Company
subsidiary which begins commercial production and widespread
distribution of SMA

4 September 30th, 2013 Nestl Investor Seminar 2013


Wyeth Nutrition key priorities

Structure the business model


to focus on premium, differentiated products

Become HCP preferred by delivering meaningful scientific innovation


and best-in-class medical marketing

Focus on highest-potential emerging markets

5 September 30th, 2013 Nestl Investor Seminar 2013


Presence in key emerging markets
Wyeth Nutrition Our customers: Our business: Our brands:
Mothers, HCPs, hospitals & Based on science
at a Glance retailers and innovation
Almost 100 year equity

Organisation size: UK/Ireland


Worldwide 4,500
Global commercial,
R&D & regulatory
Greater China Region
Asia-Pacific
Southeast Asia
Europe
Africa/Middle East
Africa and the Middle East

New Zealand
Wyeth Nutrition presence

6 September 30th, 2013 Nestl Investor Seminar 2013


Wyeth Nutrition R&D value proposition
R&D organisation
1 Early alignment provides seamless transition across development stages
1 with pediatric
Scientific and medical expertise results in compelling brand proposition
nutrition expertise

Established platforms: brain development, optimal growth and development,


Focused digestive health
2 2
research teams Coordinated R&D efforts aligned with Wyeth Nutrition brands
Partnerships with external research institutions to introduce new expertise

Close collaboration builds effective ways of working and individualised market support
Strength in Enhanced brand focus, support and discipline results in increased launches and improved
3 collaborative freshness index
brand support In 2010 less than 10% sales linked to innovation/renovation (I/R) compared to
approximately 75% sales driven by I/R in 2013

A consumer-driven, clinically-focused R&D organisation

7 September 30th, 2013 Nestl Investor Seminar 2013


State-of-the-art manufacturing
Ireland Askeaton Philippines Canlubang
ISO-certified

Experienced workforce with


deeply embedded knowledge of
the business

Discipline in execution of
requirements

Rigorous investigation and


Singapore Tuas China Suzhou
corrective action programs

8 September 30th, 2013 Nestl Investor Seminar 2013


Best-in-class medical delegates

9 September 30th, 2013 Nestl Investor Seminar 2013


Nestl and Wyeth Nutrition: the right fit
Complementary brand portfolio, scale and geographic presence

Distinct, compliant marketing and classic pharma sales capabilities

Flexible and cost competitive supply chain

R&D depth and breadth

Culture of compliance (FTSE4Good, WHO Code)

Strategy to embed not integrate the business

10 September 30th, 2013 Nestl Investor Seminar 2013


Nestl and Wyeth Nutrition > sum of its parts

Embedding enables great learning and


collaboration across the business while
maintaining two distinct divisions. We
will work hard to make the collective
whole larger than the sum of its parts
Luis Cantarell, comment in
an all-colleague letter

11 September 30th, 2013 Nestl Investor Seminar 2013


Complementary global portfolio meets diverse needs
Super premium

Premium

Standard

Economy

Healthy growth Learning & Gut health/


Benefit areas & development performance
Gut comfort
immune protection/ allergy prevention

Long term health/ early metabolic programming

12 September 30th, 2013 Nestl Investor Seminar 2013


World class portfolio: The First 1,000 Days

Bottle-Fed
Pregnancy Post-natal Breastfeeding Toddler and beyond
babies

13 September 30th, 2013 Nestl Investor Seminar 2013


Achieving an unrivaled global footprint with
Wyeth Nutrition

14 September 30th, 2013 Nestl Investor Seminar 2013


Getting to know
Wyeth Nutrition

Bill Partyka
VP Brand Management
and Innovation